Stock Scorecard
Stock Summary for Keros Therapeutics Inc (KROS) - $10.79 as of 3/28/2025 8:16:28 PM EST
Total Score
10 out of 30
Safety Score
42 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for KROS
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for KROS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for KROS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for KROS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for KROS (42 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 8 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for KROS
Financial Details for KROS
Company Overview |
|
|---|---|
| Ticker | KROS |
| Company Name | Keros Therapeutics Inc |
| Country | USA |
| Description | Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2024 |
| Next Earnings Date | 5/6/2025 |
Stock Price History |
|
| Last Day Price | 10.79 |
| Price 4 Years Ago | 58.51 |
| Last Day Price Updated | 3/28/2025 8:16:28 PM EST |
| Last Day Volume | 277,817 |
| Average Daily Volume | 816,141 |
| 52-Week High | 72.37 |
| 52-Week Low | 9.78 |
| Last Price to 52 Week Low | 10.33% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 37.01 |
| Sector PE | 40.10 |
| 5-Year Average PE | -11.19 |
| Free Cash Flow Ratio | 0.82 |
| Industry Free Cash Flow Ratio | 11.91 |
| Sector Free Cash Flow Ratio | 47.05 |
| Current Ratio Most Recent Quarter | 19.03 |
| Total Cash Per Share | 13.08 |
| Book Value Per Share Most Recent Quarter | 14.09 |
| Price to Book Ratio | 0.78 |
| Industry Price to Book Ratio | 8.86 |
| Sector Price to Book Ratio | 21.92 |
| Price to Sales Ratio Twelve Trailing Months | 129.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 88.85 |
| Sector Price to Sales Ratio Twelve Trailing Months | 27.78 |
| Analyst Buy Ratings | 6 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 40,562,000 |
| Market Capitalization | 437,663,980 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -46.15% |
| Reported EPS 12 Trailing Months | -4.88 |
| Reported EPS Past Year | -5.01 |
| Reported EPS Prior Year | -5.20 |
| Net Income Twelve Trailing Months | -181,570,000 |
| Net Income Past Year | -152,992,000 |
| Net Income Prior Year | -104,679,000 |
| Quarterly Revenue Growth YOY | 2,027.00% |
| 5-Year Revenue Growth | 81.32% |
| Operating Margin Twelve Trailing Months | -1,751.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 530,684,000 |
| Total Cash Past Year | 331,147,000 |
| Total Cash Prior Year | 279,048,000 |
| Net Cash Position Most Recent Quarter | 530,684,000 |
| Net Cash Position Past Year | 331,147,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 4,956,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 332,213,000 |
| Total Stockholder Equity Prior Year | 277,423,000 |
| Total Stockholder Equity Most Recent Quarter | 532,835,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -142,503,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.51 |
| Free Cash Flow Past Year | -126,972,000 |
| Free Cash Flow Prior Year | -71,303,000 |
Options |
|
| Put/Call Ratio | 1.52 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.25 |
| MACD Signal | -0.32 |
| 20-Day Bollinger Lower Band | -16.16 |
| 20-Day Bollinger Middle Band | 22.28 |
| 20-Day Bollinger Upper Band | 60.72 |
| Beta | 1.40 |
| RSI | 40.51 |
| 50-Day SMA | 41.56 |
| 150-Day SMA | 42.47 |
| 200-Day SMA | 43.71 |
System |
|
| Modified | 3/28/2025 12:26:49 AM EST |